Category: Blog
Precision dose measurement for the smallest patients
September 29, 2020UNC-Chapel Hill startup and KickStart Venture Services award winner Assure Technologies developed a novel medical device for precise, error-free dose measurement of medications for pediatric patients Story by Shellie Edge, photography, Sarah Daniels, Innovate Carolina The Assure Technologies device can measure the smallest doses accurately. As a patient undergoing chemotherapy, the last thing that should be on your mind is if you will receive the right dose of medication during treatment. And for parents of pediatric chemotherapy patients, where lifesaving doses are even smaller, trust in health care providers to deliver accurate measurement of medication doses is especially important. One … Read more
Carolina researchers focus on lung-mucus barrier, first line of defense against inhaled viruses
September 29, 2020An interdisciplinary team from the University of North Carolina at Chapel Hill has received funding to explore the critical role of airway mucus in the transmission, infection and spread versus protection from COVID-19. While the world waits for a vaccine against COVID-19, it is critical that we understand more about this novel virus in order to anticipate – and potentially mitigate – its spread. UNC-Chapel Hill professors M. Gregory Forestfrom the mathematics department, Ronit Freeman from the applied physical sciences department, and Samuel Lai from the Eshelman School of Pharmacy are focused on developing computational models that recapitulate the spread of COVID-19 infections in the … Read more
Pharmacy Practice Test Three
July 27, 2020By: Drew Stenger and Jon Easter, RPh Long before the COVID-19 pandemic was spreading across the globe, the U.S. was already facing an epidemic in healthcare that was spreading, costly, and ultimately unsustainable relative to healthcare spending. That epidemic is the incidence of chronic disease. Ninety percent of the total cost of healthcare in the U.S. is attributed to chronic conditions, like diabetes, heart disease, and chronic lung disorders. More than half of Americans have at least one chronic condition, with 40% having more than one. The downstream impact on patients, caregivers, providers, and payers is staggering. According … Read more
Pharmacy Practice Test – 2
July 27, 2020By: Drew Stenger and Jon Easter, RPh Long before the COVID-19 pandemic was spreading across the globe, the U.S. was already facing an epidemic in healthcare that was spreading, costly, and ultimately unsustainable relative to healthcare spending. That epidemic is the incidence of chronic disease. Ninety percent of the total cost of healthcare in the U.S. is attributed to chronic conditions, like diabetes, heart disease, and chronic lung disorders. More than half of Americans have at least one chronic condition, with 40% having more than one. The downstream impact on patients, caregivers, providers, and payers is staggering. According … Read more
Phasellus Vestibulum Eleifend Nisi, Molestie Auctor Arcu Euismod Rutrum
July 21, 2020Lorem ipsum dolor sit amet, consectetur adipisicing elit. Qui dicta minus molestiae vel beatae natus eveniet ratione temporibus aperiam harum alias officiis assumenda officia quibusdam deleniti eos cupiditate dolore doloribus! Ad dolore dignissimos asperiores dicta facere optio quod commodi nam tempore recusandae. Rerum sed nulla eum vero expedita ex delectus voluptates rem at neque quos facere sequi unde optio aliquam! Tenetur quod quidem in voluptatem corporis dolorum dicta sit pariatur porro quaerat autem ipsam odit quam beatae tempora quibusdam illum! Modi velit odio nam nulla unde amet odit pariatur at! Consequatur rerum amet fuga expedita sunt et tempora saepe? Iusto … Read more
Test Article – Drug Research Two
July 21, 2020By: Drew Stenger and Jon Easter, RPh Long before the COVID-19 pandemic was spreading across the globe, the U.S. was already facing an epidemic in healthcare that was spreading, costly, and ultimately unsustainable relative to healthcare spending. That epidemic is the incidence of chronic disease. Ninety percent of the total cost of healthcare in the U.S. is attributed to chronic conditions, like diabetes, heart disease, and chronic lung disorders. More than half of Americans have at least one chronic condition, with 40% having more than one. The downstream impact on patients, caregivers, providers, and payers is staggering. According … Read more
Test Article – Education Two
July 21, 2020Lorem ipsum dolor sit amet, consectetur adipisicing elit. Qui dicta minus molestiae vel beatae natus eveniet ratione temporibus aperiam harum alias officiis assumenda officia quibusdam deleniti eos cupiditate dolore doloribus! Ad dolore dignissimos asperiores dicta facere optio quod commodi nam tempore recusandae. Rerum sed nulla eum vero expedita ex delectus voluptates rem at neque quos facere sequi unde optio aliquam! Tenetur quod quidem in voluptatem corporis dolorum dicta sit pariatur porro quaerat autem ipsam odit quam beatae tempora quibusdam illum! Modi velit odio nam nulla unde amet odit pariatur at! Consequatur rerum amet fuga expedita sunt et tempora saepe? Iusto … Read more
With coronavirus pandemic complexity abounds, solutions are on the horizon.
July 17, 2020By: Drew Stenger and Jon Easter, RPh Long before the COVID-19 pandemic was spreading across the globe, the U.S. was already facing an epidemic in healthcare that was spreading, costly, and ultimately unsustainable relative to healthcare spending. That epidemic is the incidence of chronic disease. Ninety percent of the total cost of healthcare in the U.S. is attributed to chronic conditions, like diabetes, heart disease, and chronic lung disorders. More than half of Americans have at least one chronic condition, with 40% having more than one. The downstream impact on patients, caregivers, providers, and payers is staggering. According … Read more
Test Article – Drug Research One
July 17, 2020Lorem ipsum dolor sit amet, consectetur adipisicing elit. Qui dicta minus molestiae vel beatae natus eveniet ratione temporibus aperiam harum alias officiis assumenda officia quibusdam deleniti eos cupiditate dolore doloribus! Ad dolore dignissimos asperiores dicta facere optio quod commodi nam tempore recusandae. Rerum sed nulla eum vero expedita ex delectus voluptates rem at neque quos facere sequi unde optio aliquam! Tenetur quod quidem in voluptatem corporis dolorum dicta sit pariatur porro quaerat autem ipsam odit quam beatae tempora quibusdam illum! Modi velit odio nam nulla unde amet odit pariatur at! Consequatur rerum amet fuga expedita sunt et tempora saepe? Iusto … Read more
Biosimilar Access to Reduce Biologic Spending in the United States: A Policy Brief
July 10, 2020Biosimilars were initially projected to save as much as $150B in the specialty pharmaceuticals market. However, product launches have not kept pace with approvals, and numerous barriers to entry have become apparent. Some examples include financial disincentives for providers to administer biosimilars over originator products; lack of provider understanding of the efficacy, safety, and interchangeability of biosimilars; and finally, anticompetitive strategies employed by manufacturers to subvert biosimilar access. This combination of challenges makes launching a biosimilar product difficult.